ALX Oncology Stock Price

0.14 (1.73%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 197,141
Bid Price 7.80
Ask Price 18.03
News -
Day High 8.31


52 Week Range


Day Low 8.05
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
ALX Oncology Holdings Inc ALXO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.14 1.73% 8.23 18:54:09
Open Price Low Price High Price Close Price Prev Close
8.07 8.05 8.31 8.23 8.09
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,461 197,141 $ 8.17 $ 1,610,044 - 5.82 - 81.19
Last Trade Time Type Quantity Stock Price Currency
18:54:08 2 $ 8.64 USD


Draw Mode:

ALX Oncology Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 334.80M 40.68M 21.27M $ - $ - -2.06 -3.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 2.10%

more financials information »

ALX Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALXO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.558.317.268.04626,3910.689.01%
1 Month7.488.315.827.07748,6380.7510.03%
3 Months17.5718.485.829.02498,920-9.34-53.16%
6 Months21.9622.405.8213.22498,488-13.73-62.52%
1 Year54.7781.195.8228.05419,724-46.54-84.97%
3 Years30.44117.455.8239.07310,672-22.21-72.96%
5 Years30.44117.455.8239.07310,672-22.21-72.96%

ALX Oncology Description

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Your Recent History
ALX Oncolo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.